Xue-Ting Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xue-Ting Gong has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Xueer Li
Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China
2 shared publications - Andong Wu
Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China
1 shared publication - Bingbing Zhou
Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China
1 shared publication - Jiankun Liu
Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China
1 shared publication - Jiayi Dong
Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China
1 shared publication - Jiayu Qiu
Aging and Vascular Diseases, Human Aging Research Institute (HARI) and School of Life Sciences, Nanchang University, Nanchang 330031, China
1 shared publication
Latest Publications
- Open Access
Aqueous Extract of Fructus Choerospondiatis Peel Suppresses Vascular Inflammation and Alleviates Atherosclerosis via AKT/c-FOS/IL-6 Axis
Background: Atherosclerosis is the pathological basis for lethal cardio-cerebral vascular diseases, such as coronary artery disease and stroke. Fructus Choerospondiatis (FC) has demonstrated cardiac protective effects in multiple ethnomedicine. Whether these protective effects are attributed to the prevention of vascular atherosclerosis, however, remains unknown. We aim to examine the anti-atherosclerotic effect of FC aqueous extract and elucidate the underlying mechanism. Methods: FC was separated into peel and pulp, and the aqueous extract was obtained separately by boiling in water to mimic decocting. Atherosclerosis model was established in ApoE−/− mice fed with a high-fat diet, and histological analysis were utilized to evaluate the development of atherosclerosis. Various inflammatory models were constructed in mice to evaluate the anti-inflammatory effect of FC extract systemically, including acute local inflammation induced by traumatic injury (ear/foot swelling), acute systemic inflammation triggered by pathogenic infection (LPS- and POLY (I:C)-induced), as well as chronic inflammatory conditions associated with oxidative stress (D-galactose-induced), metabolic disorder (db/db mice), and aging. LC-MS and network pharmacology identified bioactive components and targets. Western blotting, ELISA, qPCR, and immunofluorescence were utilized to analyze the key genes involved in the mechanisms. Results: FC peel extract reduced serum IL-6 level, atherosclerotic plaque area, and macrophage content in the plaque, while pulp extract showed no protective effects. Peel extract exhibits anti-inflammatory effects in all models. The integrative application of LC-MS and network pharmacology identified ellagic acid as the major bioactive component and AKT as its target protein. Mechanistically, FC peel extract inhibits AKT phosphorylation, suppresses c-FOS expression and nuclear translocation, reduces IL-6 transcription and inflammation, and thus alleviates atherosclerosis. Conclusions: FC peel aqueous extract exerts anti-atherosclerotic effect by inhibiting inflammation through AKT/c-FOS/IL-6 axis. This study provides novel insights into the protective effects against atherosclerosis of FC peel and highlights its potential application in the prevention and treatment of coronary artery diseases.
Open AccessAqueous Extract of Fructus Choerospondiatis Peel Suppresses Vascular Inflammation and Alleviates Atherosclerosis via AKT/c-FOS/IL-6 Axis
Background: Atherosclerosis is the pathological basis for lethal cardio-cerebral vascular diseases, such as coronary artery disease and stroke. Fructus Choerospondiatis (FC) has demonstrated cardiac protective effects in multiple ethnomedicine. Whether these protective effects are attributed to the prevention of vascular atherosclerosis, however, remains unknown. We aim to examine the anti-atherosclerotic effect of FC aqueous extract and elucidate the underlying mechanism. Methods: FC was separated into peel and pulp, and the aqueous extract was obtained separately by boiling in water to mimic decocting. Atherosclerosis model was established in ApoE−/− mice fed with a high-fat diet, and histological analysis were utilized to evaluate the development of atherosclerosis. Various inflammatory models were constructed in mice to evaluate the anti-inflammatory effect of FC extract systemically, including acute local inflammation induced by traumatic injury (ear/foot swelling), acute systemic inflammation triggered by pathogenic infection (LPS- and POLY (I:C)-induced), as well as chronic inflammatory conditions associated with oxidative stress (D-galactose-induced), metabolic disorder (db/db mice), and aging. LC-MS and network pharmacology identified bioactive components and targets. Western blotting, ELISA, qPCR, and immunofluorescence were utilized to analyze the key genes involved in the mechanisms. Results: FC peel extract reduced serum IL-6 level, atherosclerotic plaque area, and macrophage content in the plaque, while pulp extract showed no protective effects. Peel extract exhibits anti-inflammatory effects in all models. The integrative application of LC-MS and network pharmacology identified ellagic acid as the major bioactive component and AKT as its target protein. Mechanistically, FC peel extract inhibits AKT phosphorylation, suppresses c-FOS expression and nuclear translocation, reduces IL-6 transcription and inflammation, and thus alleviates atherosclerosis. Conclusions: FC peel aqueous extract exerts anti-atherosclerotic effect by inhibiting inflammation through AKT/c-FOS/IL-6 axis. This study provides novel insights into the protective effects against atherosclerosis of FC peel and highlights its potential application in the prevention and treatment of coronary artery diseases.
- Open Access
- 31 October 2025
- Published by Springer Nature in Research Square
Nanotherapeutic Strategy via ADSC-mitoEVs Rescues Ischemic Angiogenesis through Mitophagy and Mitochondrial Metabolic Reprogramming
Ischemic vascular diseases are critically associated with mitochondrial dysfunction in endothelial cells, leading to impaired angiogenesis and compromised tissue repair. Although mitochondrial transfer has emerged as a promising therapeutic strategy for revascularization, its clinical translation has been hindered by inefficient delivery systems. In this study, we show that mitochondrial-enriched extracellular vesicles derived from adipose-derived stem cells (ADSC-mitoEVs) function as an efficient nanotherapeutic, restoring angiogenic function both in vitro and in a murine model of diabetic hindlimb ischemia. Mechanistically, the uptake of ADSC-mitoEVs triggered PINK1/Parkin-mediated mitophagy in recipient endothelial cells, a process essential for initiating angiogenesis. Moreover, ADSC-mitoEVs directly delivered functional mitochondrial proteins, including superoxide dismutase 2 (SOD2), into the endogenous mitochondrial network, which enhanced antioxidant defense and improved bioenergetic capacity independently of mitophagy, as shown by reduced reactive oxygen species and elevated ATP production even in PINK1-silenced cells. Our results demonstrate ADSC-mitoEVs as a versatile, cell-free nanotherapeutic that promotes mitochondrial quality control and metabolic reprogramming, offering a potent therapeutic avenue for ischemic vascular diseases.
- 31 October 2025
- Published by Springer Nature in Research Square
Open AccessNanotherapeutic Strategy via ADSC-mitoEVs Rescues Ischemic Angiogenesis through Mitophagy and Mitochondrial Metabolic Reprogramming
Ischemic vascular diseases are critically associated with mitochondrial dysfunction in endothelial cells, leading to impaired angiogenesis and compromised tissue repair. Although mitochondrial transfer has emerged as a promising therapeutic strategy for revascularization, its clinical translation has been hindered by inefficient delivery systems. In this study, we show that mitochondrial-enriched extracellular vesicles derived from adipose-derived stem cells (ADSC-mitoEVs) function as an efficient nanotherapeutic, restoring angiogenic function both in vitro and in a murine model of diabetic hindlimb ischemia. Mechanistically, the uptake of ADSC-mitoEVs triggered PINK1/Parkin-mediated mitophagy in recipient endothelial cells, a process essential for initiating angiogenesis. Moreover, ADSC-mitoEVs directly delivered functional mitochondrial proteins, including superoxide dismutase 2 (SOD2), into the endogenous mitochondrial network, which enhanced antioxidant defense and improved bioenergetic capacity independently of mitophagy, as shown by reduced reactive oxygen species and elevated ATP production even in PINK1-silenced cells. Our results demonstrate ADSC-mitoEVs as a versatile, cell-free nanotherapeutic that promotes mitochondrial quality control and metabolic reprogramming, offering a potent therapeutic avenue for ischemic vascular diseases.